Provided by Tiger Trade Technology Pte. Ltd.

Vanda Pharmaceuticals

6.20
+0.11001.81%
Pre-market: 6.310.1100+1.77%08:01 EST
Volume:1.76M
Turnover:10.84M
Market Cap:366.40M
PE:-1.66
High:6.28
Open:6.06
Low:6.02
Close:6.09
52wk High:9.60
52wk Low:3.81
Shares:59.10M
Float Shares:49.48M
Volume Ratio:1.21
T/O Rate:3.56%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.7413
EPS(LYR):-3.7413
ROE:-50.93%
ROA:-16.50%
PB:1.12
PE(LYR):-1.66

Loading ...

B. Riley Securities Keeps Their Buy Rating on Vanda (VNDA)

TIPRANKS
·
Yesterday

Cantor Fitzgerald Keeps Their Buy Rating on Vanda (VNDA)

TIPRANKS
·
Feb 15

Regulatory Hurdles Cloud Vanda Pharmaceuticals’ Prospects for Bysanti and Imsidolimab FDA Approvals

TIPRANKS
·
Feb 13

Vanda Pharmaceuticals (VNDA) Q4 Loss Surge Challenges Bullish Valuation Narratives

Simply Wall St.
·
Feb 13

Vanda Pharmaceuticals Balances Growth With Rising Risks

TIPRANKS
·
Feb 13

BRIEF-Vanda Pharmaceuticals Inc Files For Mixed Shelf Offering Of Upto $200 Million - SEC Filing

Reuters
·
Feb 12

Vanda Pharmaceuticals Inc Files for Mixed Shelf Offering of Upto $200 Mln - SEC Filing

THOMSON REUTERS
·
Feb 12

Vanda Pharmaceuticals reports Q4 EPS ($2.39) vs. (8c) last year

TIPRANKS
·
Feb 12

Vanda Pharmaceuticals sees FY26 revenue $230M-$260M, consensus $271.27M

TIPRANKS
·
Feb 12

BRIEF-Vanda Pharmaceuticals Q4 EPS USD -2.39

Reuters
·
Feb 12

Vanda Pharmaceuticals Q4 Non-GAAP net loss hits USD 106.78 million

Reuters
·
Feb 12

Vanda Pharmaceuticals Inc - FY Revenue Guidance for Currently Commercialized Products Between $230 Mln to $260 Mln

THOMSON REUTERS
·
Feb 12

Vanda Pharmaceuticals Inc. to Announce Fourth Quarter and Full Year 2025 Financial Results

Reuters
·
Feb 05

Vanda Pharmaceuticals Advances Ponesimod Into Phase 3 Psoriasis Study: What Investors Should Know

TIPRANKS
·
Jan 24

BUZZ-U.S. STOCKS ON THE MOVE-DoorDash, Duolingo, Gap

Reuters
·
Jan 09

H.C. Wainwright says rejection of Vanda’s tasimelteon ‘only minor setback’

TIPRANKS
·
Jan 08

BUZZ-U.S. STOCKS ON THE MOVE-Sigma Lithium, Darden Restaurants, Nike

Reuters
·
Jan 08

Shares of Vanda Pharmaceuticals Drop Almost 12% Premarket After U.S. FDA Rejects Jet Lag Drug Application

THOMSON REUTERS
·
Jan 08

BUZZ-Vanda falls as US FDA rejects jet lag drug application

Reuters
·
Jan 08

Vanda Pharmaceuticals down 11% to $7.55 after FDA rejects sNDA for hetlioz

TIPRANKS
·
Jan 08